GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotechnology Assets SA (XMAD:BST) » Definitions » 3-Year Revenue Growth Rate

Biotechnology Assets (XMAD:BST) 3-Year Revenue Growth Rate : -1.10% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Biotechnology Assets 3-Year Revenue Growth Rate?

Biotechnology Assets's Revenue per Share for the six months ended in Dec. 2023 was €0.04.

During the past 12 months, Biotechnology Assets's average Revenue per Share Growth Rate was 29.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was -1.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was -28.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was -20.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Biotechnology Assets was 85.00% per year. The lowest was -70.20% per year. And the median was 7.50% per year.

Competitive Comparison of Biotechnology Assets's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Biotechnology Assets's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotechnology Assets's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotechnology Assets's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Biotechnology Assets's 3-Year Revenue Growth Rate falls into.


Biotechnology Assets 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Biotechnology Assets  (XMAD:BST) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Biotechnology Assets 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Biotechnology Assets's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotechnology Assets (XMAD:BST) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotechnology Assets SA (XMAD:BST) » Definitions » 3-Year Revenue Growth Rate
Comparable Companies
XMAD:ORY OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270 BMRN XBRU:UCB RPRX LEGN
Traded in Other Exchanges
N/A
Address
Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591
Website
https://www.biatgroup.com
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.